Xanodyne Pharmaceuticals, Inc.

22 articles about Xanodyne Pharmaceuticals, Inc.

• Mallinckrodt Inc. Announces Agreement With Xanodyne Pharmaceuticals, Inc. to Purchase Roxicodone®

  8/23/2012

• Xanodyne Pharmaceuticals, Inc. Sells Drug for $26 Million to Depomed, Inc.

  6/22/2012

• Xanodyne Pharmaceuticals, Inc. Appoints New Chief Operating Officer

  5/17/2011

• Xanodyne Pharmaceuticals, Inc. to Voluntarily Withdraw Darvon(R) and Darvocet-N(R) Products

  11/19/2010

• Xanodyne Pharmaceuticals, Inc. Laying Off 60 Pct of Work Force

  9/24/2010

• Xanodyne Pharmaceuticals, Inc. Announces Natasha Giordano New President & CEO

  5/27/2010

• Ferring Pharmaceuticals Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.

  5/10/2010

• Xanodyne Pharmaceuticals, Inc. and Ferring Pharmaceuticals, Inc. Announce Co-Promote for Zipsor(TM)

  4/1/2010

• Bioniche Pharma Ltd. Adds On, Aquires Drugs from Xanodyne Pharmaceuticals, Inc.

  11/16/2009

• Xanodyne Pharmaceuticals, Inc. Expands U.S. Sales Force and Launches Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules

  11/13/2009

• Xanodyne Pharmaceuticals, Inc. Raises $50 Million in Equity Financing to Support Emerging Product Portfolio

  10/30/2009

• Xanodyne Pharmaceuticals, Inc. Announces New Executive Team Members

  7/15/2009

• FDA and Xanodyne Pharmaceuticals, Inc. Agree on a Plan to Keep Propoxyphene-Containing Products Available as Treatment Options for the Management of Mild to Moderate Pain

  7/8/2009

• Xanodyne Pharmaceuticals, Inc. Receives Approval From the FDA for ZIPSOR(TM) Liquid Filled Capsules

  6/18/2009

• Xanodyne Pharmaceuticals, Inc. Announces New President/CEO and Completes $38 Million Equity Financing

  6/4/2009

• Xanodyne Pharmaceuticals, Inc.'s New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification

  4/2/2009

• Xanodyne Pharmaceuticals, Inc. Cancels IPO Due to "Market Conditions"

  10/27/2008

• Xanodyne Pharmaceuticals, Inc. Achieves Positive Efficacy Results in Pivotal Phase 3 Studies of Proprietary Modified Release Oral Tranexamic Acid Product Candidate for Heavy Menstrual Bleeding

  8/5/2008

• Xanodyne Pharmaceuticals, Inc. Receives Approvable Letter From the U.S. FDA for ZIPSOR(TM) Capsules

  7/22/2008

• Xanodyne Pharmaceuticals, Inc. Announces Two Senior Appointments

  2/6/2008